Abstract
Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 717-729 |
| Number of pages | 13 |
| Journal | Annals of Neurology |
| Volume | 66 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2009 Dec |
Fingerprint
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Molecularly targeted therapies for glioma. / Yamanaka, Ryuya; Saya, Hideyuki.
In: Annals of Neurology, Vol. 66, No. 6, 12.2009, p. 717-729.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Molecularly targeted therapies for glioma
AU - Yamanaka, Ryuya
AU - Saya, Hideyuki
PY - 2009/12
Y1 - 2009/12
N2 - Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.
AB - Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.
UR - http://www.scopus.com/inward/record.url?scp=73549096412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=73549096412&partnerID=8YFLogxK
U2 - 10.1002/ana.21793
DO - 10.1002/ana.21793
M3 - Article
C2 - 20035507
AN - SCOPUS:73549096412
VL - 66
SP - 717
EP - 729
JO - Annals of Neurology
JF - Annals of Neurology
SN - 0364-5134
IS - 6
ER -